Ozempic has a strong overall safety profile backed by large clinical trials and nearly a decade of real-world use since its FDA approval in 2017. Most people tolerate it well enough to stay on it, though gastrointestinal side effects are common, especially in the first weeks. The serious risks are rare but real, and understanding them helps you weigh the drug’s benefits against its downsides.
What Ozempic Is Approved For
The FDA approved Ozempic (semaglutide) for three specific uses in adults with type 2 diabetes: improving blood sugar control alongside diet and exercise, reducing the risk of major cardiovascular events in people with established heart disease, and protecting kidney function in people with chronic kidney disease. It is not FDA-approved for weight loss alone, though a higher-dose version of the same drug (Wegovy) is. When doctors prescribe Ozempic off-label for weight management, the safety data still largely applies, but the context matters because dosing and patient health profiles differ.
Common Side Effects
Stomach-related problems are by far the most frequent complaint. In clinical trials of the 2.4 mg dose, about 44% of participants experienced nausea compared to 16% on placebo. Roughly 30% had diarrhea, 25% had vomiting, and 24% had constipation. These numbers are higher than many people expect, but context helps: most of these episodes were mild to moderate, peaked during the dose-escalation period (the first several weeks when your dose is gradually increased), and faded over time.
About 5% to 9% of trial participants stopped taking the drug because of gastrointestinal symptoms. That means the vast majority who experienced nausea or diarrhea found it manageable enough to continue. Eating smaller meals, avoiding high-fat foods, and staying hydrated all help reduce the severity of these effects while your body adjusts.
Cardiovascular Benefits
One of the strongest points in Ozempic’s safety record is what it does for the heart. In a large real-world study comparing semaglutide to tirzepatide (another newer medication in the same class), semaglutide was linked to a 29% lower risk of major cardiovascular events like heart attack, stroke, and cardiovascular death. These benefits appear to go beyond what weight loss alone would explain, suggesting the drug has direct protective effects on blood vessels and inflammation. For people with type 2 diabetes and existing heart disease, this is a meaningful safety advantage over older diabetes medications.
Mental Health and Suicidal Thoughts
Early reports raised concerns that GLP-1 drugs like Ozempic might increase the risk of suicidal thoughts or depression. The FDA investigated this thoroughly, analyzing 91 placebo-controlled trials covering nearly 108,000 patients. The results were clear: no increased risk of suicidal ideation, self-harm, anxiety, depression, irritability, or psychosis. A separate real-world study using insurance claims data from over 2.2 million patients confirmed those findings. Based on this evidence, the FDA in 2025 actually requested that the suicidal behavior warning be removed from GLP-1 medication labels.
Pancreatitis and Gallbladder Problems
Pancreatitis (painful inflammation of the pancreas) has been a concern with GLP-1 drugs since the early days of the drug class. The major clinical trials, including SUSTAIN-6 and LEADER, found no significant difference in confirmed acute pancreatitis between semaglutide and placebo. That said, the drug does slow digestion and affect bile flow, which can increase the risk of gallstones. If you develop sudden, severe abdominal pain that radiates to your back or is accompanied by fever, that warrants immediate medical attention regardless of the statistical rarity.
Kidney Risks From Dehydration
Ozempic itself doesn’t appear to be directly toxic to the kidneys, but its gastrointestinal side effects can create a problem indirectly. When nausea and vomiting are severe enough to cause dehydration, kidney function can decline, sometimes sharply. Reported cases of acute kidney injury in semaglutide users almost always involved patients who were already vomiting or had significant diarrhea. People with existing moderate to severe kidney disease are at higher risk because they have less kidney reserve to absorb the hit. Staying well-hydrated is especially important during the early weeks of treatment, and any signs of dehydration (dark urine, dizziness, very low fluid intake) should prompt a call to your doctor and lab work to check kidney function.
Severe Gastrointestinal Complications
Beyond the common nausea and diarrhea, the FDA updated Ozempic’s label in 2025 to include a new warning about severe gastrointestinal reactions. Postmarketing reports have identified cases of ileus (where the intestines temporarily stop moving), intestinal obstruction, and severe constipation including fecal impaction. These are rare but serious events that can require hospitalization. They’re worth knowing about because symptoms like progressively worsening constipation, bloating with an inability to pass gas, or severe abdominal pain are signals to seek care rather than wait it out.
Eye Health Considerations
People with diabetic retinopathy (damage to the blood vessels in the eye from diabetes) may see a temporary worsening of their eye condition when starting Ozempic. This is thought to be related to rapid improvements in blood sugar rather than a direct effect of the drug on the eyes. The American Academy of Ophthalmology notes that the exact mechanism is still unclear. If you have existing retinopathy, your eye doctor should be part of the conversation before you start treatment, and more frequent eye exams may be appropriate during the first year.
Pregnancy and Planning Ahead
Ozempic is not considered safe during pregnancy. The drug’s manufacturer recommends stopping it at least two months before trying to conceive. Semaglutide has a long half-life, meaning it lingers in the body. It takes roughly six weeks after your last dose for most of the drug to clear your system, which is why the two-month buffer exists. If you become pregnant while taking Ozempic, stopping the medication promptly and contacting your healthcare provider is the standard recommendation.
The Thyroid Cancer Signal
Ozempic carries a boxed warning, the FDA’s most serious type, about thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors in rodents. Whether this translates to humans remains uncertain because rodent thyroid biology differs from ours in important ways. No confirmed increase in human thyroid cancer has been established in clinical trials, but the warning exists because the possibility hasn’t been fully ruled out either. People with a personal or family history of medullary thyroid carcinoma or a rare condition called Multiple Endocrine Neoplasia syndrome type 2 should not take Ozempic.
Putting the Risks in Perspective
For the conditions Ozempic is designed to treat, uncontrolled type 2 diabetes carries its own serious dangers: heart attack, stroke, kidney failure, nerve damage, and vision loss. The drug’s cardiovascular and kidney-protective benefits are substantial and well-documented. The most common side effects are uncomfortable but temporary for most people. The rare serious complications, while important to know about, occur in a small fraction of users.
The safety picture shifts depending on your individual health. Someone with well-controlled diabetes, no kidney disease, and no history of pancreatitis faces a different risk profile than someone with advanced kidney disease or active retinopathy. The drug’s safety also depends heavily on proper use: gradual dose escalation, adequate hydration, and monitoring for warning signs during the first few months of treatment.